SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James WyncollView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James WyncollView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro GarciaView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro GarciaView Video
HMHilda MujuruMBChB, MMed Paeds, MSc Clin EpiSlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela MujuruView Slideset
HMHilda MujuruMBChB, MMed Paeds, MSc Clin EpiVideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela MujuruView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie CollinsView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie CollinsView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials - Pauline AmugeView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials - Pauline AmugeView Video
VMVictor MusiimeMBChB, MMed, PhDSlidesetHIV17th International Workshop on Pediatrics & HIV 2025Debate: All Young Adults with Perinatal HIV Should Receive a Statin to Reduce the Risk of Cardiovascular-Related Morbidity and Mortality - Con Standpoint - Victor MusiimeView Slideset
SlidesetHIVTuberculosis17th International Workshop on Pediatrics & HIV 2025Abstract #17 Effect of TB Preventive Treatment on TB Incidence and Non-TB-Related Mortality among Children and Adolescents Living with HIV Initiated on Antiretroviral Therapy in Cameroon, 2020-2022 - Boris Kevin TchoungaView Slideset
